Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.

Respirology (Carlton, Vic.) - 1 Aug 2018

Epstein Shochet Gali, Wollin Lutz, Shitrit David

Abstract excerpt

BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. Activated fibroblasts are the key effector cells in fibrosis, producing excessive amounts of collagen and extracellular matrix (ECM) proteins. Whether the ECM conditioned by IPF fibroblasts determines the phenotype of naïve fibroblasts is difficult to explore. METHODS: IPF-derived primary fibroblasts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Culture Media, Conditioned
Share to Idiopathic Pulmonary Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Laminin

Share to Primary Cell Culture

Share to Proteoglycans

Share to Pyridones

Share to Smad3 Protein

Share to STAT3 Transcription Factor

Source

Identifiers

PMID: 29532550
DOI: 10.1111/resp.13287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.PMID 29532550Read ↗

Fibrotic human lung extracellular matrix as a disease-specific substrate for 3D <i>in-vitro</i> models of pulmonary fibrosisSemantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy.Semantic proximity Read ↗

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Modeling cell-cell interactions to advance drug discovery in Idiopathic Pulmonary FibrosisSemantic proximity Read ↗

Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 CellsSemantic proximity Read ↗

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.Semantic proximity Read ↗

Profibrotic priming of airway cell types and drug responses in early-stage idiopathic pulmonary fibrosisSemantic proximity Read ↗

Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesisSemantic proximity Read ↗

Targeting the epithelium in pulmonary fibrosis.Semantic proximity Read ↗

Inhibition of fibrosis with multi-agent therapy in pulmonary fibrosis: Results of a drug library screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.